Apotex has received Health Canada approval for its Bambevi bevacizumab rival to Avastin, with the firm citing the nod as a first for its Apobiologix division.
Apotex has received Health Canada approval for its Bambevi (bevacizumab) biosimilar rival to Avastin, with the Canadian giant’s Apobiologix unit billing the product as “its first therapeutic treatment.”
Previously, Apobiologix has received Canadian approval for and launched Grastofil (filgrastim) in 2016 and Lapelga (pegfilgrastim) in 2019, with the latter representing “the first-ever pegfilgrastim biosimilar approved in any highly regulated market
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.
